DexCom (DXCM) – Analysts’ Recent Ratings Changes

DexCom (NASDAQ: DXCM) recently received a number of ratings updates from brokerages and research firms:

• 10/13/2026 – DexCom was given a new $100.00 price target by Mizuho.
• 10/12/2026 – DexCom had its price target raised by BTIG Research from $90.00 to $96.00. They now have a “buy” rating on the stock.
• 10/7/2026 – DexCom was upgraded by Barclays PLC to “strong-buy”.
• 10/6/2026 – DexCom is now covered by Barclays PLC. They set an “overweight” rating and a $115.00 price target on the stock.
• 10/6/2026 – DexCom was upgraded by Weiss Ratings from “hold (c)” to “hold (c+)”.
• 10/1/2026 – DexCom had its “outperform” rating reaffirmed by Royal Bank Of Canada. They now have a $105.00 price target on the stock, up from $90.00.
• 9/18/2026 – DexCom was given a new $102.00 price target by Truist Financial Corporation. They now have a “buy” rating on the stock.
• 9/18/2026 – DexCom had its “buy” rating reaffirmed by TD Cowen. They now have a $95.00 price target on the stock.
• 9/6/2026 – DexCom was upgraded by Wall Street Zen from “hold” to “buy”.
• 8/29/2026 – DexCom was downgraded by Wall Street Zen from “buy” to “hold”.

Insider Buying and Selling

In related news, EVP Sadie Stern sold 2,565 shares of the stock in a transaction dated Monday, September 28th. The stock was sold at an average price of $86.15, for a total transaction of $220,974.75. Following the completion of the sale, the executive vice president directly owned 123,478 shares in the company, valued at $10,637,629.70. This represents a 2.04% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Brown sold 1,700 shares of DexCom stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $85.48, for a total value of $145,316.00. Following the completion of the transaction, the executive vice president directly owned 98,185 shares in the company, valued at $8,392,853.80. This trade represents a 1.70% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 24,257 shares of company stock worth $2,049,173 over the last 90 days. Insiders own 0.28% of the company’s stock.

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its devices use a small wearable sensor to measure glucose levels in real time and transmit readings to compatible smartphones, receivers, smartwatches, and other connected devices, helping users monitor glucose trends and make informed decisions about their health.

The company’s product portfolio includes the Dexcom G7 and Dexcom G6 CGM systems, as well as Dexcom ONE and Dexcom ONE+ products offered in select markets.